Major drugmakers including Chong Kun Dang, Dong-A ST and Ildong Pharmaceutical held annual shareholder meetings on March 26, approving agenda items as proposed, including new director appointments and cash dividends aimed at boosting shareholder value.
According to the industry, Chong Kun Dang held its 13th annual general meeting that morning at its headquarters in Chungjeong-ro. Shareholders approved a cash dividend of 500 won per share, equal to 20% of par value.
In opening remarks, Chong Kun Dang CEO Kim Young-joo said the company would “deliver profit growth this year” by launching new products on schedule, strengthening product competitiveness and improving market responsiveness. He said it would also raise drug development efficiency through Achela, described as an NRDO (No Research Development Only) specialist, and “increase corporate value” by building a Baegot bio complex development cluster to secure biotech competitiveness.
Chong Kun Dang Holdings also held its 71st annual general meeting on March 26. The company reported 2025 consolidated revenue of 959 billion won and operating profit of 58.3 billion won, and approved a cash dividend of 1,400 won per share, equal to 56% of par value.
Dong-A ST held its 13th annual general meeting at its headquarters in Seoul’s Dongdaemun district, approving six items as proposed, including approval of financial statements, amendments to the articles of incorporation and director appointments.
Shareholders approved a cash dividend of 700 won per common share and a stock dividend of 0.05 shares per share. The meeting also approved a 30 billion won reduction in capital reserves and a transfer to retained earnings to secure funding for tax-exempt dividends.
CEO Jeong Jae-hoon said the company is also stepping up investment in digital health care, which he said will be central to future medical technology, and is building a foundation for growth.
Dong-A Socio Holdings also held its 78th annual general meeting at its headquarters in Seoul’s Dongdaemun district.
Shareholders approved five items as proposed: approval of the 78th financial statements and consolidated financial statements, partial amendments to the articles of incorporation, director appointments, appointment of an outside director who will serve on the audit committee, and approval of the cap on director compensation. They also approved a cash dividend of 1,000 won per share and a stock dividend of 0.03 shares per share. The company said the dividend is tax-exempt and not subject to dividend income tax.
Ildong Pharmaceutical and Ildong Holdings each held annual shareholder meetings on March 26 at Ildong Pharmaceutical’s headquarters in Seoul’s Seocho district.
Ildong Pharmaceutical CEO Yoon Woong-seop said the company will focus this year, under its management policy of “creating results with competitive advantage,” on generating sales and profit, securing new growth engines and building a sustainable business structure, while strengthening its core businesses such as pharmaceuticals and concentrating capabilities on future growth including R&D.
At the meeting, all agenda items were approved as proposed, including approval of financial statements, partial amendments to the articles of incorporation, and the appointment of directors and an auditor.
Ildong Holdings also approved its agenda items as proposed, including approval of financial statements reflecting its dividend plan, partial amendments to the articles of incorporation, and the appointment of directors and an auditor.
Ildong Holdings CEO Park Dae-chang said the company will continue to pursue management efficiency and reform across group affiliates to strengthen its business foundation and build momentum for growth, adding that it also plans to work to enhance corporate value and increase shareholder returns.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.